



Bringing Science to Supplements

December 2018



ANATARA
LIFESCIENCES

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anantara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.

Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.

Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.

Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.



Key Investor Message

Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need.



Anatara Corporate History



Key Management & Board of Directors



Steve Lydeamore, CEO

- 25+ years international pharmaceutical experience in Australia, USA and Canada
- Lead roles in global business development, manufacturing and finance, including the commercialisation of numerous consumer drug products
- MBA, CPA, GAICD



Sue MacLeman, Chair

- 30+ years pharmaceutical, biotechnology and medical technology experience in corporate, medical, commercial and business development
- Has served as CEO and Board member of several ASX and NASDAQ listed companies
- MBA, LLM, ATSE Fellow, AICD



Dr Michael West, COO

- 25+ years in the pharmaceutical industry internationally
- Medicinal chemist with lead roles in drug discovery, drug development and manufacture
- Qualified Patent and Trademark Attorney



Dr Tracie Ramsdale, Director

- 30+ years drug discovery, design and development experience
- Multiple corporate financing transactions and product licensing deals with global pharmaceutical and manufacturing companies
- MPharm, PhD, ATSE Fellow, AICD



Dr Tracey Brown, CDO

- 20+ years experience in biotechnology and pharmaceutical product development – from conception to registration and reimbursement
- Lead roles in research institutions in USA & Australia
- Assoc Prof Monash University – research commercialisation



Dr Jane Ryan, Director

- 30+ years international experience in the pharmaceutical and biotechnology industries
- VP Product Development & Strategic Marketing and Director of Business Development at Biota Holdings Ltd (Relenza)
- Led multiple successful fundraising campaigns and licensing initiatives including the awarding of a \$230m US Gov contract

Key Financial Details

ASX Code ANR	Market Capitalisation¹ \$22.2 million	Share Price¹ \$0.45
Current Cash² \$7.1 million	Ordinary Shares 49,413,236	Options 2,346,000

1. As at 30 November 2018

2. Appendix 4C - 30 September 2018




Company Highlights

- Negotiated an exclusive **global licensing agreement** for the worldwide development, distribution and marketing of Detach with **Zoetis Inc - leading global animal health company**
- Detach received regulatory approval from **Australian Pesticides and Veterinary Medicines Authority (APVMA)** for use in piglets
- Growth in Anatar's skill set, with key appointments with significant **human health experience**:
 - Sue MacLeman and Dr Jane Ryan, to the Board of Directors, and
 - Steven Lydeamore as CEO



Company Highlights Cont.

- **Human development** program well underway - developing scientifically innovative and commercially attractive products for **gastrointestinal health** in areas of **critical need**
- First product candidate - **Gastrointestinal ReProgramming (GaRP) dietary supplement** is aimed at restoring and maintaining **gut health** - proof of concept studies are well advanced
- Formation of our **Product Development Advisory Board**
 - World-leading scientists and clinicians in gastrointestinal health
- Company well funded with \$7.1m in bank
 - ~\$1,230,000 **R&D tax refund** received for 2016-17 activities
 - **Sufficiently funded** to execute on the development and partnering of our GaRP dietary supplement



Animal Health

- Detach is a natural, safe, non-antibiotic product that **aids in the control of diarrhoea** (known as scour) in livestock
- In May 2018, Anantara signed an **exclusive licensing agreement** with **Zoetis Inc.**, the leading global animal health company, for the **worldwide development, manufacturing, distribution, and marketing of Detach** for livestock animals and horses
- Upfront payment of US\$2.5m, aggregate milestone payments of up to US\$6.3m and royalty of 3-4%
- In October 2018, the Australian Pesticides and Veterinary Medicines Authority (**APVMA**) **registered Detach for use in piglets in Australia**





From animals to humans

Anatara's Technology

- **Bromelain** is a natural product extracted from pineapple stems.
- Based on decades of research by world-class academic and commercial partners which found that bromelain contains a number of proteases with distinct biological activities, including
 - Anti-attachment
 - Anti-secretory
 - Anti-inflammatory


Potential applications in humans include gastrointestinal (GI) diseases that involve inflammation and/or diarrhoea



Anatara molecules are extracted from "stems" of the pineapple plant

About Irritable Bowel Syndrome (IBS)

- IBS is a functional disorder. Incomplete knowledge of pathology, therefore the approach is symptom management
- Symptoms include abdominal pain, bloating and alternating constipation and diarrhoea
- Patients have a poor quality of life and utilise the healthcare system more than other patients
- ~50% of patients² turn to dietary supplements and complementary medicines



25B USD
GI and Digestive
Health
Nutraceuticals
Market*

36B USD
by 2021
CAGR 8%*

Affects
around 11%
of the global
population¹

IBS is the most commonly diagnosed gastrointestinal condition and a significant health care burden

About Inflammatory Bowel Disease (IBD)

- Two forms: Ulcerative Colitis and Crohn's Disease
- Patients experience abdominal pain and cramping, bloating, blood and mucus in the stool, loss of appetite and persistent diarrhoea
- Treatment involves suppressing inflammation with the goal of inducing and maintaining remission
- 30-50% of IBD patients⁴ turn to complementary and alternative medicines



>5m
IBD sufferers
worldwide³

**IBD is a global disease with
accelerating incidence in newly
industrialised countries**


Anatara has designed a novel product aimed at restoring and maintaining gut health:

Gastrointestinal ReProgramming (GaRP) Dietary Supplement

For the Management of
Gastrointestinal Disorders



Target Gastrointestinal Disorders



IBS and IBD are areas of significantly unmet clinical need

Anatara's GaRP aims to:

- Re-establish the homeostasis of the gut microbiome
- Treat the inflammation
- Repair the mucosal damage

THEREBY reduce the associated diarrhoea.



The Microbiome and IBS/IBD

Healthy gut microbiome

- Supplies energy and nutrients
- Immune system development
- Defence against pathogens



Healthy gut – increased diversity

IBD/IBS gut microbiome


- Less bacteria with anti-inflammatory properties
- More bacteria with pro-inflammatory properties
- Reduction of diversity
- Change in overall bacteria numbers



Unhealthy gut – lack of diversity

How GaRP works

GaRP is a microbiome-targeted dietary supplement aimed at:



GaRP will be used as an **adjunct** to existing treatments.



Dietary Supplements as an adjunct to prescription drugs for the treatment of GI disorders

- ~50% of patients seek additional relief of their symptoms through adjunct therapies
- Increased education and more detailed evaluation of dietary supplements has led to health-care providers working with patients to develop individualised programs which include dietary supplements in the symptom management for GI disorders.



GaRP – built on strong
scientific foundations



About Bromelain



Generally Recognised as Safe (GRAS)

Bromelain is allowed in food as a food additive and it has been affirmed as Generally Recognised as Safe (GRAS) allowing it to be **considered as a food**.



Unlimited Acceptable Daily Intake (ADI)

Bromelain has been used for decades in as an anti-inflammatory and anti-cancer complementary medicine in the USA and Europe. This has established it to be safe with an **unlimited Acceptable Daily Intake**



But formal clinical data has been lacking

A lot of anecdotal evidence regarding its clinical efficacy but the bromelain is poorly characterised and therefore has variable activity resulting in **no definitive clinical data**



Until now...

Anatara has developed a **bromelain fingerprint** where different biological activities are associated with specific parts of the bromelain fingerprint

This will be utilised in our human therapeutic programs



Dual targeted product
combining bromelain and
other GRAS components*

Ileum targeted components

- prevent attachment of pro-inflammatory bacteria
- restore gut microbiota
- reduce inflammation

Colon targeted components

- restore gut microbiota
- reduce inflammation
- mucosa regeneration
- restore gut integrity
- reduce diarrhoea



Ileum

Colon

GaRP Development Plan

- **Commercial Feasibility** - confirming the clinical and market need for a multi-functional dietary supplement that could act as an adjunct to current IBD and IBS medications.
- **Proof of concept studies** are well advanced to demonstrate that GaRP can:
 - Remove bacteria with pro-inflammatory properties
 - Reduce inflammation by reducing the release of proinflammatory cytokines
 - Regenerate the integrity of the gastrointestinal tract
 - Stimulate mucosal healing
- **Formulation Development** – coated, dual-release preparation
- **Efficacy Testing** – in relevant animal disease models



Regulatory Advantages of Dietary Supplements*





The advantages of a dietary supplement regulatory strategy are:

1. Less expensive and less risky pathway to market
2. Rapid market entry
3. Public and health care professionals understand the term 'dietary supplement'
4. Marketing can be aimed at both the public and the professional.

* Dietary Supplement are foods intended to supplement the normal diet which are concentrated sources of one or more nutrients, like vitamins, proteins, mineral complexes, herb or other botanical, amino acid or enzymes.



A Clear Path to Commercialisation

	2017 H1	2017 H2	2018 H1	2018 H2	2019 H1	2019 H2	2020 H1	2020 H2
Confirmed GRAS status for components with FDA	✓							
Established collaboration with University of Liverpool (UK)		✓						
Completed product development plan		✓						
Patent Application filed				✓				
Commercial feasibility			✓					
Manufacturing – sourced suppliers		✓						
Proof of concept								
Efficacy studies								
Partnering discussions								 *



Product Development Advisory Board



Professor Peter Gibson



Dr Rebecca Burgell



Dr Jakob Begun



Professor Barry Campbell



Professor Simon Keely

- Advisory Board members are internationally recognised for their expertise in IBS and IBD with experience ranging from preclinical drug development through to translational research and clinical trials.
- The role of the Advisory Board is provide advice on Anantara's research and product development programs in gastrointestinal health.





Thank you



ANATARA
LIFESCIENCES